Weight Loss Drug Index Completed Periodic Rebalance
The Amplify Weight Loss Drug & Treatment ETF updated its holdings after its underlying index added two new pharmaceutical firms.
Updated on Sept. 21, 2026 in Weight Loss
Live Poll
Is now a good time for you to invest in targeted medical innovation funds?
The VettaFi Weight Loss Drug & Treatment Index completed a scheduled rebalance on September 18, 2026, dropping Scholar Rock and Hims & Hers while adding Gilead Sciences and Structure Therapeutics. The Amplify Weight Loss Drug & Treatment ETF adjusted its portfolio to reflect these changes as the broader market continues to evolve.
Why it matters
This rebalance reflects a shift in the pharmaceutical industry toward oral pills, monthly dosing, and muscle-sparing treatments. Industry leaders are aiming to capture a share of a weight-loss drug market projected to grow to $150 billion by 2035.
Eli Lilly comprised nearly 10% of the fund's assets, while AstraZeneca and Roche Holding accounted for 5.4% and 5.3% of the index weight, respectively. Gilead Sciences represented 5.2% of the fund's assets shortly after the September 18 rebalance.
The players
Eli Lilly
This major pharmaceutical company is a key player in the weight-loss drug sector and expects to file for regulatory approval of its drug Retatrutide in 2027.
AstraZeneca
This multinational pharmaceutical corporation is actively developing oral weight-loss treatments and maintains a significant weight in the sector index.
Roche Holding
This healthcare company is investing in specialized weight-loss treatments, including recent licensing deals for muscle-sparing drugs.
Gilead Sciences
This biopharmaceutical company was recently added to the weight-loss index following the September 2026 rebalance.
Hims & Hers Health
This telehealth company focuses on consumer health products and was removed from the index following significant year-to-date valuation declines.
The details
The rebalance was necessitated by rapid developments in the sector, including AstraZeneca moving an oral weight-loss pill into Phase III in June 2026 and Roche licensing a muscle-sparing drug in August 2026. Companies like Hims & Hers have faced volatility, losing nearly half their value year to date, while Merck & Co. has seen a 42.4% gain.
Timeline
AstraZeneca moved an oral weight-loss pill into Phase III in June 2026.
Roche licensed a muscle-sparing weight-loss drug in August 2026.
The index rebalance occurred on September 18, 2026.
Eli Lilly plans to file Retatrutide with the FDA in early 2027.
The global weight-loss drug market is projected to reach $150 billion by 2035.
Health Landscape
The index rebalance aligns with the industry's focus on the $150 billion 2035 market projection, signaling investor efforts to capture long-term growth. This move positions the fund to participate in the evolving shift toward diverse treatment delivery methods like oral medications.
The shift toward oral pills and muscle-sparing treatments may eventually provide patients with more accessible and targeted weight-loss options. Ongoing research suggests that these new pharmaceutical developments could change the standard of care for obesity treatment in the coming years.
The takeaway
Investors and patients alike should monitor the transition from injectable to oral weight-loss medications as firms diversify their pipelines. This move signals a broader industry effort to improve treatment flexibility and therapeutic outcomes.
What happens next
Eli Lilly is scheduled to file its weight-loss drug Retatrutide with the FDA in early 2027.
Further reading
For more information on the evolving sector, visit our Weight Loss section.
Live Poll
Is now a good time for you to invest in targeted medical innovation funds?
